Bisantrene Combination for Resistant AML

  • STATUS
    Recruiting
  • End date
    Dec 1, 2025
  • participants needed
    29
  • sponsor
    Sheba Medical Center
Send
Updated on 30 September 2021
See if I qualify
fludarabine
carbon monoxide
ejection fraction
clofarabine

Summary

An Open-label, Phase II, Two-stage, Study of Xantrene (Bisantrene) in combination with Fludarabine and Clofarabine as Salvage Therapy for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) Lead-in stage: up to 12 (up to 2 cohorts in a 3+3 dose escalation design) Efficacy stage: up to 17 (Simon 2-stage design 9+8)

Study Objectives:

  • Confirm safety and tolerability of the combination regimen
  • Time to response with combination treatment
  • Overall survival

The treatment regimen will comprise daily IV infusion of Fludarabine (Flu), Clofarabine (Clo) and Bisantrene (Xan) administered via central venous line and controlled-rate infusion pump with a 1-hour break between each agent infusion, amounting to a total of 6 hours for each daily FluCloXan treatment in the following sequence:

  • First, infusion over 60 minutes of Fludarabine (Flu) at 10 mg/m2
  • Followed by infusion of Clofarabine (Clo) at 30 mg/m2 over 60 minutes
  • Followed by infusion of Bisantrene (Xan) at 250 mg/m2 over 2 hours. One cycle will comprise daily IV infusion of the combination treatment course for 4 or 5 consecutive days and rest period to between Day 30 and Day 42, based on patient performance and disease status.

Details
Condition Acute Myelogenous Leukemia (AML), Acute myeloid leukemia, Acute Myeloid Leukemia
Treatment Fludarabine, Clofarabine, Bisantrene
Clinical Study IdentifierNCT04989335
SponsorSheba Medical Center
Last Modified on30 September 2021

Eligibility

 Yes No Not Sure

Inclusion Criteria

Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written Informed Consent and privacy language as per national regulations
Age 18 -65 (inclusive) years
Diagnosis of AML by World Health Organization (WHO) classification (WHO, 2016) and have received at least one line of therapy prior to enrollment into this study
Eastern Cooperative Oncology Group (ECOG) performance status 2.0
Life expectancy 3 months
Adequate organ function as evidenced by serum total bilirubin 2.0 mg/dL, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 4 the upper limit of normal (ULN), serum albumin >2.8 g/dL, serum creatinine 2 mg/dL
Cardiac ejection fraction 50%, assessed by 2-Dimensional echocardiogram
Pulmonary function 50% assessed by diffusing capacity for carbon monoxide (DLCO), and any clinically significant decrease in DLCO must not be caused by infection
Negative for serum markers for HIV, Hepatitis -B, -C, and HTLV-1
Clinically significant non-hematologic toxicity after prior chemotherapy has recovered to Grade 1 per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Females must be surgically or biologically sterile or postmenopausal (amenorrhoeic for at least 12 months) or if of childbearing potential, must have a negative urine or serum pregnancy test within 14 days before study entry, and must agree to use an adequate method of contraception, i.e. barrier method, during the study until 30 days after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception, i.e. barrier method, during the study until 30 days after the last treatment

Exclusion Criteria

Acute promyelocytic leukemia (APML, APL) M3 subtype of AML
Other active malignancy (including other hematologic malignancies) or other malignancy within the last 12 months except non-melanoma skin cancer or cervical intraepithelial neoplasia
Prior or current therapy
Hydroxyurea or other oral medications to reduce blast count within 72 hours before the first dose of study drug
Treatment with an investigational agent within 14 days before the first dose of study drug, or not recovered from all acute effects of previous investigational therapy
Last treatment was with a drug of long elimination half-life (e.g. enasidenib), as such a wash out period 5x elimination half-life is necessary prior to enrollment
For patients who have undergone hematopoietic stem cell transplantation (HSCT), procedure-related medications (e.g. immunosuppressive therapy) administered within 2 weeks prior to first dose of study drug
Any medical, psychological, or social condition that may interfere with study participation or compliance or may compromise the patient's safety in the opinion of the investigator
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

fludarabine
carbon monoxide
ejection fraction
clofarabine

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note